- Home
- OUT vs KNSA Comparison
OUT vs KNSA Comparison
Compare OUT & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OUT | KNSA |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.9B |
| IPO Year | 2013 | 2018 |
Fundamental Metrics
Financial Performance| Metric | OUT | KNSA |
|---|---|---|
| Price | $28.21 | $75.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $38.00 | ★ $98.00 |
| AVG Volume (30 Days) | ★ 1.2M | 402.2K |
| Earning Date | 11-05-2026 | 10-27-2026 |
| Dividend Yield | ★ 4.76% | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | ★ 0.54 | 0.27 |
| Revenue | ★ $1,831,700,000.00 | $677,564,000.00 |
| Revenue This Year | $9.12 | $46.66 |
| Revenue Next Year | $2.62 | $22.90 |
| P/E Ratio | ★ $52.06 | $280.98 |
| Revenue Growth | 0.04 | ★ 60.09 |
| 52 Week Low | $16.97 | $35.53 |
| 52 Week High | $34.96 | $82.94 |
Technical Indicators
Market Signals| Indicator | OUT | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 31.76 | 44.07 |
| Support Level | $25.41 | $74.47 |
| Resistance Level | $28.08 | $81.42 |
| Average True Range (ATR) | 0.57 | 2.37 |
| MACD | 0.04 | -0.46 |
| Stochastic Oscillator | 5.45 | 24.47 |
Price Performance
Historical ComparisonAbout OUT OUTFRONT Media Inc.
Outfront Media Inc is a real estate investment trust involved in the ownership of advertising space on its portfolio of billboards and transit displays. The company has two reportable operating segments: Billboard and Transit. It derives maximum revenue from Billboard Segment. The company geographically operates in United States and Canada, of which United States derive maximum revenue.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.